PD-1抑制剂治疗相关中枢性尿崩症1例

摘要
图/表
参考文献
相关文章 (2)

[1]	Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors[J]. Allergol Int, 2022,71 (2):169-178.
[2]	中华医学会内分泌学分会免疫内分泌学组. 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)[J]. 中华内分泌代谢杂志, 2021, 37(1):1-16.
[3]	Barnabei A, Strigari L, Corsello A, et al. Immune checkpoint inhibitor-induced central diabetes insipidus: looking for the needle in the haystack or a very rare side-effect to promptly diagnose?[J]. Front Oncol, 2022,12: 1-11.
[4]	傅艺满, 杨奕, 朱延华, 等. 程序性死亡受体1抑制剂导致的垂体炎病例一例[J]. 中华医学杂志, 2021, 101(44): 3670-3671.
[5]	冀笑燕, 金鹏, 王清泉. 程序性死亡蛋白1抑制剂导致自身免疫性垂体炎1例[J]. 中华内科杂志, 2022, 61 (3): 321-324.
[6]	王林杰, 袁涛, 段炼, 等. 一例PD-1抑制剂相关垂体炎的诊治[J]. 中华内分泌代谢杂志, 2019,35 (7): 554-558.
[7]	龚劭敏, 陈晓泓, 章晓燕, 等. 抗肿瘤治疗中出现多种肾损伤表现一例[J]. 上海医学, 2021,44 (9):661-665.
[8]	Brilli L, Calabrò L, Campanile M, et al. Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy[J]. Arch Endocrinol Metab, 2020,64(4):483-486.
[9]	Deligiorgi M V, Siasos G, Vergadis C, et al. Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy[J]. Int Immunopharmacol, 2020, 83:1-8.
[10]	Yu M X,Liu L, Shi P F,et al. Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report[J]. Immunotherapy, 2021, 13 (15):1255-1260.
[11]	Zhao C, Harsha T S, Jaydira D R, et al. Anti-PD-L1 treatment induced central diabetes insipidus[J]. J Clin Endocrinol Metab, 2018, 103(2): 365-369.
[12]	Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)(Article)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[13]	陈家伦, 宁光, 潘长玉, 等. 临床内分泌学[M] :上海:上海科学技术出版社,2011:247-254.
[14]	李苹,张会娟. 尿崩症121例病因分析[J]. 中国实用医刊, 2018,45(15):18-20.
[15]	潘杰,陈正光,炎洪珍,等. 中枢性尿崩症的MR影像诊断(附65例分析)[J]. 中国医学影像学杂志, 1997,5(2):65-68.
[16]	陈灏珠, 钟南山, 陆再英, 等. 内科学[M]. 9版. 北京:人民卫生出版社,2018: 673-675.
[17]	Balanescu S, Kopp P, Gaskill M B, et al. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states(Article)[J]. J Clin Endocrinol Metabol, 2011, 96 (4):1046-1052.
[18]	乐颖, 王元阳, 彭全洲, 等. 累及垂体和甲状腺的成人朗格汉斯细胞组织细胞增生症1例[J]. 中华内科杂志, 2022,61(3): 327-330.
[19]	王艳妮,崔莉,陈楠,等. 肉芽肿性多血管炎垂体受累临床分析并文献复习[J]. 中日友好医院学报, 2018, 32(6):347-351,320.
[20]	John K, Varvara V, Despina P, et al. Tumors metastatic to the pituitary gland: case report and literature review[J]. J Clin Endocrinol Metab, 2004, 89 (2):574-580.
[21]	He W Z,Chen F X, Brian D, et al. Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis [J]. Pituitary, 2015,18(1):159-168.
[22]	Fassett D R, Couldwell W T. Metastases to the Pituitary Gland [J]. Neurosurg Focus, 2004,16(4):E8.
[23]	王诺金,张楠,邓大通,等. 以尿崩症为首发表现的垂体转移性肿瘤临床特征分析[J] . 中国全科医学, 2018, 21(18):2231-2237, 2241.
[24]	Shing Chang L, Barroso-Sousa R, Tolaney S M, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J]. Endocr Rev, 2019, 40 (1):17-65.
[25]	Okabe N, Kobayashi T, Furuse J, et al. An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma[J]. Pathol Int, 2021, 71 (12):31-836.